|Day's Range||53.30 - 53.30|
|52 Week Range||51.70 - 68.03|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low. Earlier this month, the drugmaker said U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application. The company, which makes and markets branded and non-branded generic and injectable drugs, now expects full-year revenue to be in the range of $2 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.
Morgan Stanley has a couple of pointers for Amazon's entry into the pharma market.
ST. LOUIS, May 18, 2017 /PRNewswire/ -- Express Scripts Holding Company (NASDAQ: ESRX), through a wholly owned subsidiary, Innovative Product Alignment, LLC, today announced it will participate in Walgreens ...